Array Announces Changes to Board
Array BioPharma (NASDAQ: ARRY) announced that Francis Bullock, Ph.D., and Kevin Koch, Ph.D., have decided not to stand for reelection to its Board of Directors and that David Snitman, Ph.D., intends to resign from the Board of Directors. Each of the directors will be leaving the Board effective following Array's Annual Meeting of Stockholders to be held on October 24, 2012. Dr. Koch and Dr. Snitman will continue their leadership roles on Array's executive team, with Dr. Koch continuing to serve as President and Chief Scientific Officer and Dr. Snitman continuing to serve as Chief Operating Officer and Vice President of Business Development. Dr. Bullock decided not to stand for reelection so that he could devote more time to his other personal and professional responsibilities. A search is underway to add independent directors with industry knowledge, skills and expertise to guide Array in achieving its goal of becoming a commercial-stage biopharmaceutical company.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.